Jonathan Northrup

Jonathan Northrup is an accomplished executive with extensive experience in the pharmaceutical and biotechnology industries. Currently serving as a Board Member and Advisor at Vasculonics since September 2020, Jonathan also holds the position of CEO, Co-Founder, and Board Member at Stingray Therapeutics, which focuses on novel immune oncology modulators. Additionally, Jonathan is a Board Member for Iterion Therapeutics and Salarius Pharmaceuticals, the latter of which Jonathan co-founded. Previously, Jonathan was the CEO and co-founder of Beta Cat Pharmaceuticals, where the company developed inhibitors targeting the β-catenin pathway in cancer treatment. Jonathan's professional journey also includes being the COO of Jubilant Innovation and founding Horizon Biotechnologies, along with serving as VP of Business Development and Strategy at Eli Lilly. Jonathan holds an MBA from The Wharton School and a Bachelor of Arts in Economics from Northwestern University.